Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Cervical Cancer-Pipeline Review, H2 2016

Cervical Cancer-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Cervical Cancer-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer-Pipeline Review, H2 2016, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 20, 29, 1, 39, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 1, 9 and 5 molecules, respectively.Cervical Cancer.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Cervical Cancer Overview 12

Therapeutics Development 13

Pipeline Products for Cervical Cancer-Overview 13

Pipeline Products for Cervical Cancer-Comparative Analysis 14

Cervical Cancer-Therapeutics under Development by Companies 15

Cervical Cancer-Therapeutics under Investigation by Universities/Institutes 21

Cervical Cancer-Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Unknown Stage Products 25

Cervical Cancer-Products under Development by Companies 26

Cervical Cancer-Products under Investigation by Universities/Institutes 33

Cervical Cancer-Companies Involved in Therapeutics Development 34

Abion Inc 34

Admedus Ltd 35

Advaxis Inc 36

Advenchen Laboratories LLC 37

Antigen Express Inc 38

Arbor Vita Corp 39

ArQule Inc 40

AstraZeneca Plc 41

AVEO Pharmaceuticals Inc 42

Azaya Therapeutics Inc 43

Bioleaders Corporation 44

Biomics Biotechnologies Co Ltd 45

Blirt SA 46

Boehringer Ingelheim GmbH 47

Bristol-Myers Squibb Company 48

Cancer Research Technology Ltd 49

Cell Medica Ltd 50

Cellceutix Corp 51

Coherus BioSciences Inc 52

Critical Outcome Technologies Inc 53

CZ BioMed Corp 54

DelMar Pharmaceuticals, Inc. 55

Dr. Reddy's Laboratories Ltd 56

EirGenix Inc. 57

Eisai Co Ltd 58

Etubics Corp 59

Eureka Therapeutics Inc 60

EyeGene Inc 61

F. Hoffmann-La Roche Ltd 62

Formune SL 63

GamaMabs Pharma SA 64

Gene Techno Science Co Ltd 65

Genexine Inc 66

Genmab A/S 67

Genor BioPharma Co Ltd 68

Genticel S.A. 69

GlaxoSmithKline Plc 70

Immune Therapeutics, Inc. 71

Immunovaccine Inc 72

INSYS Therapeutics Inc 73

ISA Pharmaceuticals BV 74

Johnson & Johnson 75

Karyopharm Therapeutics Inc 76

Kite Pharma Inc 77

LondonPharma Ltd 78

Mabion SA 79

Merck & Co Inc 80

Mycenax Biotech Inc 81

Nanotherapeutics Inc 82

Nektar Therapeutics 83

Oncobiologics Inc 84

Ono Pharmaceutical Co Ltd 85

Oryx GmbH & Co KG 86

PDS Biotechnology Corp 87

Pfizer Inc 88

Psicofarma SA de CV 89

Rexahn Pharmaceuticals Inc 90

Richter Gedeon Nyrt 91

Samyang Holdings Corp 92

Sanofi 93

Savoy Pharmaceuticals, Inc. 94

Seattle Genetics Inc 95

Selecta Biosciences Inc 96

Shantha Biotechnics Ltd 97

Sirnaomics Inc 98

Sun Pharma Advanced Research Company Ltd 99

Taiho Pharmaceutical Co Ltd 100

Tessa Therapeutics Pte Ltd 101

Theravectys SA 102

THEVAX Genetics Vaccine USA Inc 103

Tomegavax Inc 104

UbiVac LLC 105

VLPbio 106

Zeria Pharmaceutical Co Ltd 107

Zydus Cadila Healthcare Ltd 108

Cervical Cancer-Therapeutics Assessment 109

Assessment by Monotherapy Products 109

Assessment by Combination Products 110

Assessment by Target 111

Assessment by Mechanism of Action 116

Assessment by Route of Administration 121

Assessment by Molecule Type 123

Drug Profiles 125

(hydralazine + valproate magnesium)-Drug Profile 125

ABN-301-Drug Profile 126

AEH-10p-Drug Profile 127

AL-3818-Drug Profile 128

Ancer-Drug Profile 130

Antisense RNAi Oligonucleotide for Cervical Cancer-Drug Profile 131

Aptamer to Target HPV E7 Protein for Cervical Cancer-Drug Profile 132

ARQ-092-Drug Profile 133

artemether-Drug Profile 136

atezolizumab-Drug Profile 138

AV-203-Drug Profile 152

AVC-7-Drug Profile 155

axalimogene filolisbac-Drug Profile 156

AZD-5363-Drug Profile 173

bevacizumab biosimilar-Drug Profile 176

bevacizumab biosimilar-Drug Profile 178

bevacizumab biosimilar-Drug Profile 179

bevacizumab biosimilar-Drug Profile 180

bevacizumab biosimilar-Drug Profile 181

bevacizumab biosimilar-Drug Profile 182

bevacizumab biosimilar-Drug Profile 183

bevacizumab biosimilar-Drug Profile 184

bevacizumab biosimilar-Drug Profile 185

bevacizumab biosimilar-Drug Profile 186

bevacizumab biosimilar-Drug Profile 187

BLR-111-Drug Profile 188

BLSILSB-710c-Drug Profile 189

BMS-986016-Drug Profile 190

BVAC-C-Drug Profile 192

Cellular Immunotherapy for HPV Associated Cancers-Drug Profile 193

Cellular Immunotherapy for Oncology-Drug Profile 194

Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer-Drug Profile 195

Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer-Drug Profile 197

CerviVax-Drug Profile 199

Cervlysis-Drug Profile 200

CIGB-300-Drug Profile 201

CMD-004-Drug Profile 203

COTI-2-Drug Profile 204

crocetin-Drug Profile 212

dianhydrogalactitol-Drug Profile 213

docetaxel-Drug Profile 225

DPXE-7-Drug Profile 227

E-7046-Drug Profile 228

EDA-HPVE7-Drug Profile 229

EDOB-278-Drug Profile 230

EF-022-Drug Profile 231

EG-HPV-Drug Profile 232

Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer-Drug Profile 233

ET-1502-Drug Profile 234

ETBX-041-Drug Profile 235

etirinotecan pegol-Drug Profile 236

GM-102-Drug Profile 242

GSK-2256098-Drug Profile 244

GSK-2849330-Drug Profile 246

GTL-001-Drug Profile 247

GTL-002-Drug Profile 250

GX-I7-Drug Profile 251

HPViNT-Drug Profile 252

human papillomavirus vaccine-Drug Profile 253

human papillomavirus vaccine-Drug Profile 254

human papillomavirus vaccine-Drug Profile 255

human papillomavirus vaccine-Drug Profile 256

human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar-Drug Profile 257

ISA-101-Drug Profile 258

JNJ-61610588-Drug Profile 261

Kevetrin-Drug Profile 262

KITE-439-Drug Profile 273

LN-145-Drug Profile 274

Lovaxin S-Drug Profile 276

Monoclonal Antibody Conjugate to Target CD40 for Cervical, Head And Neck Cancer-Drug Profile 277

naltrexone hydrochloride-Drug Profile 278

nimotuzumab-Drug Profile 281

nintedanib-Drug Profile 285

NIT-02-Drug Profile 295

nivolumab-Drug Profile 296

NP-001-Drug Profile 330

NTO-1151-Drug Profile 331

Oncoprev-Drug Profile 333

OTAC-DCtag-Drug Profile 334

paclitaxel-Drug Profile 335

paclitaxel-Drug Profile 337

paclitaxel albumin free-Drug Profile 341

PDS-0101-Drug Profile 342

pembrolizumab-Drug Profile 344

PF-04518600-Drug Profile 382

phosphoethanolamine-Drug Profile 384

RA-190-Drug Profile 385

Recombinant Protein to Inhibit NFKB for Cervical Cancer and Breast Cancer-Drug Profile 386

RG-7876-Drug Profile 387

RX-3117-Drug Profile 388

S-009131-Drug Profile 393

SAR-408701-Drug Profile 394

SEL-701-Drug Profile 395

selinexor-Drug Profile 396

SGN-LIV1A-Drug Profile 415

sirolimus albumin-bound-Drug Profile 417

Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology-Drug Profile 419

STP-900-Drug Profile 420

Subunit Vaccine for HPV Associated Cervical Cancer-Drug Profile 421

Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology-Drug Profile 422

TA-CIN-Drug Profile 423

TAS-114-Drug Profile 424

Tenacinol-Drug Profile 425

tisotumab vedotin-Drug Profile 426

TT-12-Drug Profile 428

TVGV-1-Drug Profile 429

utomilumab-Drug Profile 430

Vaccine for HPV Associated Cancers-Drug Profile 432

Vaccine for HPV Associated Cervical Cancer-Drug Profile 433

Vaccine for HPV Associated Cervical Cancer-Drug Profile 434

Vaccine for HPV Associated Cervical Cancer-Drug Profile 435

Vaccine for Human papillomavirus Associated Cervical Cancer-Drug Profile 436

Vaccine to Target HIG2, VEGFR-1 and VEGFR-2 for Ovarian Cancer and Cervical Cancer-Drug Profile 437

Vaccine to Target HPV E7 Protein for Cervical Cancer-Drug Profile 438

Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer-Drug Profile 439

Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer-Drug Profile 440

Vicoryx-Drug Profile 441

Vvax-001-Drug Profile 442

Cervical Cancer-Dormant Projects 443

Cervical Cancer-Discontinued Products 450

Cervical Cancer-Product Development Milestones 451

Featured News & Press Releases 451

Appendix 463

Methodology 463

Coverage 463

Secondary Research 463

Primary Research 463

Expert Panel Validation 463

Contact Us 463

Disclaimer 46

List of Figures

Number of Products under Development for Cervical Cancer, H2 2016 21

Number of Products under Development for Cervical Cancer-Comparative Analysis, H2 2016 22

Number of Products under Development by Companies, H2 2016 23

Number of Products under Investigation by Universities/Institutes, H2 2016 29

Comparative Analysis by Clinical Stage Development, H2 2016 31

Comparative Analysis by Early Stage Products, H2 2016 32

Assessment by Monotherapy Products, H2 2016 117

Number of Products by Top 10 Targets, H2 2016 119

Number of Products by Stage and Top 10 Targets, H2 2016 119

Number of Products by Top 10 Mechanism of Actions, H2 2016 124

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 124

Number of Products by Top 10 Routes of Administration, H2 2016 129

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 129

Number of Products by Top 10 Molecule Types, H2 2016 131

Number of Products by Stage and Top 10 Molecule Types, H2 2016 131

List of Tables

Number of Products under Development for Cervical Cancer, H2 2016 21

Number of Products under Development for Cervical Cancer-Comparative Analysis, H2 2016 22

Number of Products under Development by Companies, H2 2016 23

Number of Products under Development by Companies, H2 2016 (Contd..1) 24

Number of Products under Development by Companies, H2 2016 (Contd..2) 25

Number of Products under Development by Companies, H2 2016 (Contd..3) 26

Number of Products under Development by Companies, H2 2016 (Contd..4) 27

Number of Products under Development by Companies, H2 2016 (Contd..5) 28

Number of Products under Investigation by Universities/Institutes, H2 2016 29

Comparative Analysis by Late Stage Development, H2 2016 30

Comparative Analysis by Clinical Stage Development, H2 2016 31

Comparative Analysis by Early Stage Development, H2 2016 32

Comparative Analysis by Unknown Stage Development, H2 2016 33

Products under Development by Companies, H2 2016 34

Products under Development by Companies, H2 2016 (Contd..1) 35

Products under Development by Companies, H2 2016 (Contd..2) 36

Products under Development by Companies, H2 2016 (Contd..3) 37

Products under Development by Companies, H2 2016 (Contd..4) 38

Products under Development by Companies, H2 2016 (Contd..5) 39

Products under Development by Companies, H2 2016 (Contd..6) 40

Products under Investigation by Universities/Institutes, H2 2016 41

Cervical Cancer-Pipeline by Abion Inc, H2 2016 42

Cervical Cancer-Pipeline by Admedus Ltd, H2 2016 43

Cervical Cancer-Pipeline by Advaxis Inc, H2 2016 44

Cervical Cancer-Pipeline by Advenchen Laboratories LLC, H2 2016 45

Cervical Cancer-Pipeline by Antigen Express Inc, H2 2016 46

Cervical Cancer-Pipeline by Arbor Vita Corp, H2 2016 47

Cervical Cancer-Pipeline by ArQule Inc, H2 2016 48

Cervical Cancer-Pipeline by AstraZeneca Plc, H2 2016 49

Cervical Cancer-Pipeline by AVEO Pharmaceuticals Inc, H2 2016 50

Cervical Cancer-Pipeline by Azaya Therapeutics Inc, H2 2016 51

Cervical Cancer-Pipeline by Bioleaders Corporation, H2 2016 52

Cervical Cancer-Pipeline by Biomics Biotechnologies Co Ltd, H2 2016 53

Cervical Cancer-Pipeline by Blirt SA, H2 2016 54

Cervical Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2016 55

Cervical Cancer-Pipeline by Bristol-Myers Squibb Company, H2 2016 56

Cervical Cancer-Pipeline by Cancer Research Technology Ltd, H2 2016 57

Cervical Cancer-Pipeline by Cell Medica Ltd, H2 2016 58

Cervical Cancer-Pipeline by Cellceutix Corp, H2 2016 59

Cervical Cancer-Pipeline by Coherus BioSciences Inc, H2 2016 60

Cervical Cancer-Pipeline by Critical Outcome Technologies Inc, H2 2016 61

Cervical Cancer-Pipeline by CZ BioMed Corp, H2 2016 62

Cervical Cancer-Pipeline by DelMar Pharmaceuticals, Inc., H2 2016 63

Cervical Cancer-Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 64

Cervical Cancer-Pipeline by EirGenix Inc., H2 2016 65

Cervical Cancer-Pipeline by Eisai Co Ltd, H2 2016 66

Cervical Cancer-Pipeline by Etubics Corp, H2 2016 67

Cervical Cancer-Pipeline by Eureka Therapeutics Inc, H2 2016 68

Cervical Cancer-Pipeline by EyeGene Inc, H2 2016 69

Cervical Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 70

Cervical Cancer-Pipeline by Formune SL, H2 2016 71

Cervical Cancer-Pipeline by GamaMabs Pharma SA, H2 2016 72

Cervical Cancer-Pipeline by Gene Techno Science Co Ltd, H2 2016 73

Cervical Cancer-Pipeline by Genexine Inc, H2 2016 74

Cervical Cancer-Pipeline by Genmab A/S, H2 2016 75

Cervical Cancer-Pipeline by Genor BioPharma Co Ltd, H2 2016 76

Cervical Cancer-Pipeline by Genticel S.A., H2 2016 77

Cervical Cancer-Pipeline by GlaxoSmithKline Plc, H2 2016 78

Cervical Cancer-Pipeline by Immune Therapeutics, Inc., H2 2016 79

Cervical Cancer-Pipeline by Immunovaccine Inc, H2 2016 80

Cervical Cancer-Pipeline by INSYS Therapeutics Inc, H2 2016 81

Cervical Cancer-Pipeline by ISA Pharmaceuticals BV, H2 2016 82

Cervical Cancer-Pipeline by Johnson & Johnson, H2 2016 83

Cervical Cancer-Pipeline by Karyopharm Therapeutics Inc, H2 2016 84

Cervical Cancer-Pipeline by Kite Pharma Inc, H2 2016 85

Cervical Cancer-Pipeline by LondonPharma Ltd, H2 2016 86

Cervical Cancer-Pipeline by Mabion SA, H2 2016 87

Cervical Cancer-Pipeline by Merck & Co Inc, H2 2016 88

Cervical Cancer-Pipeline by Mycenax Biotech Inc, H2 2016 89

Cervical Cancer-Pipeline by Nanotherapeutics Inc, H2 2016 90

Cervical Cancer-Pipeline by Nektar Therapeutics, H2 2016 91

Cervical Cancer-Pipeline by Oncobiologics Inc, H2 2016 92

Cervical Cancer-Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 93

Cervical Cancer-Pipeline by Oryx GmbH & Co KG, H2 2016 94

Cervical Cancer-Pipeline by PDS Biotechnology Corp, H2 2016 95

Cervical Cancer-Pipeline by Pfizer Inc, H2 2016 96

Cervical Cancer-Pipeline by Psicofarma SA de CV, H2 2016 97

Cervical Cancer-Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 98

Cervical Cancer-Pipeline by Richter Gedeon Nyrt, H2 2016 99

Cervical Cancer-Pipeline by Samyang Holdings Corp, H2 2016 100

Cervical Cancer-Pipeline by Sanofi, H2 2016 101

Cervical Cancer-Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 102

Cervical Cancer-Pipeline by Seattle Genetics Inc, H2 2016 103

Cervical Cancer-Pipeline by Selecta Biosciences Inc, H2 2016 104

Cervical Cancer-Pipeline by Shantha Biotechnics Ltd, H2 2016 105

Cervical Cancer-Pipeline by Sirnaomics Inc, H2 2016 106

Cervical Cancer-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 107

Cervical Cancer-Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 108

Cervical Cancer-Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 109

Cervical Cancer-Pipeline by Theravectys SA, H2 2016 110

Cervical Cancer-Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2016 111

Cervical Cancer-Pipeline by Tomegavax Inc, H2 2016 112

Cervical Cancer-Pipeline by UbiVac LLC, H2 2016 113

Cervical Cancer-Pipeline by VLPbio, H2 2016 114

Cervical Cancer-Pipeline by Zeria Pharmaceutical Co Ltd, H2 2016 115

Cervical Cancer-Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 116

Assessment by Monotherapy Products, H2 2016 117

Assessment by Combination Products, H2 2016 118

Number of Products by Stage and Target, H2 2016 120

Number of Products by Stage and Mechanism of Action, H2 2016 125

Number of Products by Stage and Route of Administration, H2 2016 130

Number of Products by Stage and Molecule Type, H2 2016 132

Cervical Cancer-Dormant Projects, H2 2016 451

Cervical Cancer-Dormant Projects (Contd..1), H2 2016 452

Cervical Cancer-Dormant Projects (Contd..2), H2 2016 453

Cervical Cancer-Dormant Projects (Contd..3), H2 2016 454

Cervical Cancer-Dormant Projects (Contd..4), H2 2016 455

Cervical Cancer-Dormant Projects (Contd..5), H2 2016 456

Cervical Cancer-Dormant Projects (Contd..6), H2 2016 457

Cervical Cancer-Discontinued Products, H2 2016 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abion Inc , Admedus Ltd , Advaxis Inc , Advenchen Laboratories LLC , Antigen Express Inc , Arbor Vita Corp , ArQule Inc , AstraZeneca Plc , AVEO Pharmaceuticals Inc , Azaya Therapeutics Inc , Bioleaders Corporation , Biomics Biotechnologies Co Ltd , Blirt SA , Boehringer Ingelheim GmbH , Bristol-Myers Squibb Company , Cancer Research Technology Ltd , Cell Medica Ltd , Cellceutix Corp , Coherus BioSciences Inc , Critical Outcome Technologies Inc , CZ BioMed Corp , DelMar Pharmaceuticals, Inc. , Dr. Reddy's Laboratories Ltd , EirGenix Inc. , Eisai Co Ltd , Etubics Corp , Eureka Therapeutics Inc , EyeGene Inc , F. Hoffmann-La Roche Ltd , Formune SL , GamaMabs Pharma SA , Gene Techno Science Co Ltd , Genexine Inc , Genmab A/S , Genor BioPharma Co Ltd , Genticel S.A. , GlaxoSmithKline Plc , Immune Therapeutics, Inc. , Immunovaccine Inc , INSYS Therapeutics Inc , ISA Pharmaceuticals BV , Johnson & Johnson , Karyopharm Therapeutics Inc , Kite Pharma Inc , LondonPharma Ltd , Mabion SA , Merck & Co Inc , Mycenax Biotech Inc , Nanotherapeutics Inc , Nektar Therapeutics , Oncobiologics Inc , Ono Pharmaceutical Co Ltd , Oryx GmbH & Co KG , PDS Biotechnology Corp , Pfizer Inc , Psicofarma SA de CV , Rexahn Pharmaceuticals Inc , Richter Gedeon Nyrt , Samyang Holdings Corp , Sanofi , Savoy Pharmaceuticals, Inc. , Seattle Genetics Inc , Selecta Biosciences Inc , Shantha Biotechnics Ltd , Sirnaomics Inc , Sun Pharma Advanced Research Company Ltd, Taiho Pharmaceutical Co Ltd , Tessa Therapeutics Pte Ltd , Theravectys SA , THEVAX Genetics Vaccine USA Inc , Tomegavax Inc , UbiVac LLC , VLPbio , Zeria Pharmaceutical Co Ltd , Zydus Cadila Healthcare Ltd

Cervical Cancer Therapeutic Products under Development, Key Players in Cervical Cancer Therapeutics, Cervical Cancer Pipeline Overview, Cervical Cancer Pipeline, Cervical Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com